− Givosiran Achieved a 74 Percent Mean Reduction in Composite Annualized Attack Rate (AAR) Relative to Placebo, with Consistent Reductions Across all Components of Composite Endpoint and Subgroups – − ...

Acute hepatic porphyria, or AHP, is a group of rare genetic conditions that affect how the body makes a natural substance called heme. Heme is produced in the liver and is essential for many important ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company and its collaborators will present at the 2019 ...

MISSISSAUGA, ON, Dec. 23, 2024 /CNW/ - Alnylam Canada ULC is pleased to announce that GIVLAARI ® (givosiran injection) is now funded across Canada through both public and private insurance plans for ...

Patients with symptomatic acute hepatic porphyria were found to be at greater risk of accessing long-term sick leave and disability pension compared with the general population, but were not shown to ...

Study results published in PLoS One strongly suggest machine learning can be an effective approach to identify patients who should receive a diagnostic biochemical test to screen for acute hepatic ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) ...

ZUG, Switzerland and BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Amalia is an Alnylam patient ambassador and was sponsored to share her story through art. At first, Amalia was like any other college freshman — excited for new adventures, eager to meet new friends ...

(BPT) – Can you imagine waking up every day in excruciating pain and not knowing why? A new documentary-short explores the real-life experiences and stories of people like Sharon, who led a healthy, ...